Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Equity Income: 2024

Historic Equity Income for Ani Pharmaceuticals (ANIP) over the last 1 years, with Dec 2024 value amounting to $6.3 million.

  • Ani Pharmaceuticals' Equity Income rose 131.73% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $560,000, marking a year-over-year change of. This contributed to the annual value of $6.3 million for FY2024, which is N/A change from last year.
  • Per Ani Pharmaceuticals' latest filing, its Equity Income stood at $6.3 million for FY2024.
  • Ani Pharmaceuticals' 5-year Equity Income high stood at $6.3 million for FY2024, and its period low was $6.3 million during FY2024.
  • Moreover, its 1-year median value for Equity Income was $6.3 million (2024), whereas its average is $6.3 million.